There are various pathogenic reasons of NSCLC, and while there are a few treatments approved for NSCLC, yet EGFR exon 20 insertion, accounting 4~13% of NSCLC, is known to have no approved treatment.
While immune checkpoint inhibitors showed promising therapeutic outcomes in many types of solid tumors, EGFR exon20 insertion mutation-driven NSCLC is the field where such PD-L1 inhibitor failed in clinical trials. Especially once brain metastasis happens (=tumor expands into the brain), there is not many therapeutic options left for patients to choose other than radiotherapy that accompanies several adverse effects.
In mice EGFR Exon 20 insertion mutations xenograft animal study, VRN07-treated group showed a significant decreased tumor size making it almost invisible, whereas no-treatment group showed rapid growth of tumor. Some of mice appeared to have complete tumor remission because tumor did not grow back even after two weeks of no treatment. This implies that VRN07 may completely cure NSCLC patient with EGFR exon 20 insertion mutation. Moreover VRN07 shows little weight loss and other toxicity, making it a very safe anti-cancer agent.
ORIC-114(VRN07) has been licensed out to ORIC Pharmaceuticals, a US based pharmaceutical company, with worldwide territory excluding Greater China. Phase 1/2 clinical trials are expected to begin in the second half of 2021. Moreover, Dr. Pasi A. Jänne, a professor of Harvard Dana-Farber Cancer Institute (DFCI) is a member of Scientific Advisory Board (SAB), after years of consulting Voronoi’s lung cancer pipeline.